Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | PKM | P14618 | 2/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | NAMPT | P43490 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | BCL6 | P41182 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15510403 | 0.83 | MAPT (0.74) | MAPTPKMKDM4ELMNAALDH1A1 | |
| SCHEMBL525722 | 0.80 | ALDH1A1 (0.57) | ATG4BMAPTPKMNPC1RAB9A | |
| SCHEMBL29972743 | 0.80 | ALDH1A1 (0.57) | ATG4BMAPTPKMNPC1RAB9A | |
| SCHEMBL4629194 | 0.80 | RAB9A (0.55) | PKMNPC1RAB9AKDM4ELMNA | |
| SCHEMBL1465824 | 0.80 | ATG4B (0.56) | ATG4BMAPTPKMNPC1RAB9A | |
| SCHEMBL13333219 | 0.80 | RAB9A (0.55) | MAPTPKMNPC1RAB9AKDM4E | |
| SCHEMBL805874 | 0.80 | LMNA (0.57) | ATG4BMAPTPKMNPC1RAB9A | |
| SCHEMBL11186307 | 0.78 | PKM (0.69) | MAPTPKMNPC1RAB9AKDM4E | |
| SCHEMBL23220314 | 0.77 | MAPT (0.61) | MAPTPKMKDM4EALDH1A1KMT2A | |
| SCHEMBL17975563 | 0.77 | ATG4B (0.53) | ATG4BMAPTPKMNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2389395-B1 | RAFT POLYMERISATION | COMMW SCIENT IND RES ORG (AU) | 2017-03-29 | — | — | EP | disclosed |
| US-9340498-B2 | Raft polymerisation | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESERACH ORGANISATION (AU) | 2016-05-17 | — | — | US | disclosed |
| US-20120004381-A1 | RAFT POLYMERISATION | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2012-01-05 | — | — | US | disclosed |
| EP-2389395-A1 | RAFT POLYMERISATION | Commonwealth Scientific and Industrial Research Organisation (AU) | 2011-11-30 | — | — | EP | disclosed |
| US-20110256644-A1 | MASKS FOR MICROLITHOGRAPHY AND METHODS OF MAKING AND USING SUCH MASKS | MICRON TECHNOLOGY, INC. (US) | 2011-10-20 | — | — | US | disclosed |
| WO-2010083569-A1 | RAFT POLYMERISATION | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2010-07-29 | — | — | WO | disclosed |
| EP-0295695-B1 | Pyrazoline derivatives and agents for treating cerebrovascular diseases containing the same as active ingredient | MITSUI TOATSU CHEMICALS (JP) | 1994-06-08 | — | — | EP | disclosed |
| US-4990529-A | Nervous system disorder | MITSUI TOATSU CHEMICALS (JP) | 1991-02-05 | — | — | US | disclosed |
| US-4839376-A | Pyrazoline derivatives for treating cerebrovascular diseases | MITSUI TOATSU CHEMICALS, INC. (JP) | 1989-06-13 | — | — | US | disclosed |
| EP-0295695-A2 | Pyrazoline derivatives and agents for treating cerebrovascular diseases containing the same as active ingredient | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1988-12-21 | — | — | EP | disclosed |
| US-4039550-A | ANTHELMINTIC AGENTS | STERLING DRUG INC. (US) | 1977-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004381-A1 | RAFT POLYMERISATION | OXGR1, FRG1, MSR1 | ATG4B 4141/4885MAPT 4573/4885PKM 4237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.